Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FTC’s Stern POM Opinion Expands Disease Claim Findings

This article was originally published in The Pink Sheet Daily

Executive Summary

The Federal Trade Commission’s 5-0 decision against POM Wonderful finds the firm made false and misleading claims and requires it to conduct at least two randomized controlled clinical trials for all future disease-related claims. POM vows to appeal the order in federal court.

You may also be interested in...

FTC Could Open Arms For Health Claim Science In Regulatory Review

FTC is implementing Trump administration directives on "eliminating wasteful, unnecessary regulations and processes," but attempting to reduce regulated industries' compliance burden is not the same as slowing FTC enforcement against false and misleading advertising, attorneys say.

POM Decision Will Free FTC Resources For Other Enforcement

With the POM Wonderful litigation off its desk, FTC will have more resources to bring cases against other advertisers, attorney Mark Ullman warns. Likely target areas in 2013 and beyond include social media marketing and more subtle disease claims.

POM Wonderful Says Interviews Fall Outside FTC Advertising Scope

Claims about the benefits of pomegranate made in unpaid-for media appearances should not qualify as “advertising” under the FTC Act, argues POM Wonderful. Among the claims FTC is pursuing, POM owner Lynda Resnick told Newsweek that pomegranate juice is “40 percent as effective as Viagra.”


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts